I76 Stock Overview A healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Ironwood Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Ironwood Pharmaceuticals Historical stock prices Current Share Price US$3.70 52 Week High US$14.50 52 Week Low US$2.96 Beta 0.40 1 Month Change 12.80% 3 Month Change 2.21% 1 Year Change -63.00% 3 Year Change -64.42% 5 Year Change -69.92% Change since IPO -54.86%
Recent News & Updates
Third quarter 2024 earnings released: EPS: US$0.02 (vs US$0.098 in 3Q 2023) Nov 09
Ironwood Pharmaceuticals, Inc. Maintains Earnings Guidance for Full Year 2024 Nov 08
Investor sentiment deteriorates as stock falls 15% Sep 09
Investor sentiment deteriorates as stock falls 31% Aug 15
New minor risk - Shareholder dilution Aug 10
New minor risk - Financial position Aug 09 See more updates
Third quarter 2024 earnings released: EPS: US$0.02 (vs US$0.098 in 3Q 2023) Nov 09
Ironwood Pharmaceuticals, Inc. Maintains Earnings Guidance for Full Year 2024 Nov 08
Investor sentiment deteriorates as stock falls 15% Sep 09
Investor sentiment deteriorates as stock falls 31% Aug 15
New minor risk - Shareholder dilution Aug 10
New minor risk - Financial position Aug 09
Second quarter 2024 earnings released: US$0.005 loss per share (vs US$6.84 loss in 2Q 2023) Aug 09
Ironwood Pharmaceuticals, Inc. Revises Earnings Guidance for Its Fiscal Year 2024 Aug 08
New major risk - Share price stability Jul 29 Ironwood Pharmaceuticals, Inc.(NasdaqGS:IRWD) dropped from Russell 2000 Growth-Defensive Index
Insufficient new directors Jul 01
Independent Director recently sold €479k worth of stock Jun 13
CEO & Director recently sold €402k worth of stock May 23
Ironwood Pharmaceuticals, Inc. Revised Earnings Guidance for Its Fiscal Year 2024 May 10
First quarter 2024 earnings released: US$0.03 loss per share (vs US$0.30 profit in 1Q 2023) May 09
Ironwood Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2024 Apr 28
New minor risk - Shareholder dilution Apr 26
Ironwood Pharmaceuticals, Inc. Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD) Mar 28
New minor risk - Insider selling Feb 18
Full year 2023 earnings released: US$6.45 loss per share (vs US$1.13 profit in FY 2022) Feb 16
Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024 Feb 16
Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Fiscal Year 2024 Feb 15
Ironwood Pharmaceuticals, Inc. Maintains Earnings Guidance for the Fiscal Year 2023 and Provides Earnings Guidance for the Fiscal Year 2024 Jan 08 Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD) completed the acquisition of VectivBio Holding AG (NasdaqGS:VECT) from Versant Venture Capital V, L.P., managed by Versant Venture Management, LLC, Forbion Growth Opportunities Fund II, managed by Forbion Capital Partners B.V., OrbiMed Advisors LLC and others. Dec 13
Ironwood Pharmaceuticals, Inc. provides Earnings Guidance for the Year 2023 Nov 11
Ironwood Pharmaceuticals, Inc. Provids Earnings Guidance for the Year 2023 Nov 10
Third quarter 2023 earnings released: EPS: US$0.10 (vs US$0.33 in 3Q 2022) Nov 10
Ironwood Pharmaceuticals, Inc. Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting Oct 24
Ironwood Pharmaceuticals, Inc. Presents Positive Final Data from Stars Nutrition, A Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity Oct 17
Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old Oct 06
Senior VP recently bought €281k worth of stock Sep 20
New major risk - Negative shareholders equity Aug 09
Second quarter 2023 earnings released: US$6.84 loss per share (vs US$0.24 profit in 2Q 2022) Aug 09
Ironwood Pharmaceuticals, Inc. Revises Financial Guidance for the Year 2023 Aug 09
Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD) completed the acquisition of VectivBio Holding AG (NasdaqGS:VECT) from Versant Venture Capital V, L.P., managed by Versant Venture Management, LLC, Forbion Growth Opportunities Fund II, managed by Forbion Capital Partners B.V., OrbiMed Advisors LLC and others. Jun 30
Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old Jun 13
CEO & Director recently sold €337k worth of stock May 26
Ironwood Pharmaceuticals, Inc. Presents Results from Phase III Clinical Trial in Pediatric Patients May 09
First quarter 2023 earnings released: EPS: US$0.30 (vs US$0.25 in 1Q 2022) May 05
Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2023 May 05
Senior VP & COO recently sold €366k worth of stock Mar 02
Full year 2022 earnings released: EPS: US$1.13 (vs US$3.26 in FY 2021) Feb 17
Ironwood Pharmaceuticals, Inc. Provides Financial Guidance for 2023 Feb 17
Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application for LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old Feb 14 Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2023
Senior VP & COO recently sold €314k worth of stock Dec 18
Senior VP recently sold €74k worth of stock Nov 25
Third quarter 2022 earnings released: EPS: US$0.33 (vs US$0.34 in 3Q 2021) Nov 04
Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022 Nov 04
Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of Linzess® (Linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation Sep 07
Senior VP & COO recently sold €335k worth of stock Aug 12
Second quarter 2022 earnings released: EPS: US$0.24 (vs US$2.42 in 2Q 2021) Aug 05
Ironwood Pharmaceuticals, Inc. Provides Financial Guidance for the Year 2022 Aug 05
High number of new directors May 31 Ironwood Pharmaceuticals, Inc. to Present New IW-3300 and Linaclotide Data at Digestive Disease Week® 2022 May 10
First quarter 2022 earnings released: EPS: US$0.25 (vs US$0.25 in 1Q 2021) May 07
Ironwood Pharmaceuticals, Inc. Provides Financial Guidance for the Full Year 2022 May 06
High number of new directors Apr 27
Ironwood Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2022 Apr 22
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 18
Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022 Feb 18 Ironwood Pharmaceuticals, Inc. Provides Financial Guidance for the Full Year 2022
Executive Chairman of the Board recently sold €98k worth of stock Dec 17
Third quarter 2021 earnings released: EPS US$0.34 (vs US$0.21 in 3Q 2020) Nov 07
Ironwood Pharmaceuticals Announces FDA Approval of Revised Linzess® (Linaclotide) Label Aug 27
Second quarter 2021 earnings released: EPS US$2.42 (vs US$0.16 in 2Q 2020) Aug 06
Principal Accounting Officer, CFO, Senior VP & Treasurer Gina Consylman has left the company Jul 06
Ironwood Pharmaceuticals Announces The American Journal of Gastroenterology Publishes Full Results from Positive LINZESS® (linaclotide) Phase IIIb Trial in Adults with Irritable Bowel Syndrome with Constipation (IBS-C) Jun 17 Ironwood Pharmaceuticals, Inc. Maintains Earnings Guidance for the Full Year 2021
First quarter 2021 earnings released: EPS US$0.25 (vs US$0.021 in 1Q 2020) May 07
CEO & Director Mark Mallon has left the company Mar 17
Investor sentiment improved over the past week Mar 06
Independent Director recently bought €90k worth of stock Mar 01
Principal Accounting Officer & VP of Finance has left the company Feb 21
Full year 2020 earnings released: EPS US$0.67 (vs US$0.38 in FY 2019) Feb 19
Revenue beats expectations Feb 19
New 90-day low: €8.20 Feb 16 Ironwood Pharmaceuticals, Inc. Announces Board Changes
Ironwood Pharmaceuticals, Inc. Announces Executive Changes Dec 18
Ironwood Pharmaceuticals Appoints Jay P. Shepard to Board of Directors Dec 04 Ironwood Pharmaceuticals, Inc. Updates Financial Guidance for the Year 2020
Ironwood Pharmaceuticals, Inc. Announces Data from IW-3718-302 Sep 30
New 90-day low: €7.50 Sep 29 Shareholder Returns I76 DE Biotechs DE Market 7D 10.8% -3.5% -2.0% 1Y -63.0% -14.7% 6.9%
See full shareholder returns
Return vs Market: I76 underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is I76's price volatile compared to industry and market? I76 volatility I76 Average Weekly Movement 11.3% Biotechs Industry Average Movement 6.8% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: I76's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: I76's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis.
Show more Ironwood Pharmaceuticals, Inc. Fundamentals Summary How do Ironwood Pharmaceuticals's earnings and revenue compare to its market cap? I76 fundamental statistics Market cap €682.50m Earnings (TTM ) -€2.36m Revenue (TTM ) €362.68m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) I76 income statement (TTM ) Revenue US$378.42m Cost of Revenue US$125.41m Gross Profit US$253.01m Other Expenses US$255.48m Earnings -US$2.46m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.015 Gross Margin 66.86% Net Profit Margin -0.65% Debt/Equity Ratio -192.3%
How did I76 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 14:14 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Ironwood Pharmaceuticals, Inc. is covered by 37 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Raghuram Selvaraju Aegis Capital Corporation Geoffrey Meacham Barclays Patrick Trucchio Berenberg
Show 34 more analysts 
